文献速递细菌感染、耐药与抗菌药物医院感染防控

ME1100吸入用阿贝卡星优化制剂在铜绿假单胞菌呼吸机相关肺炎小鼠模型中的疗效与药代动力学:与阿米卡星比较

Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

本研究在铜绿假单胞菌所致呼吸机相关肺炎小鼠模型中,使用定制雾化系统每日一次5分钟吸入ME1100(3、10、30 mg/mL)或阿米卡星30 mg/mL。结果显示10和30 mg/mL ME1100组生存率较安慰剂显著提高,30 mg/mL组初始治疗后6小时肺内细菌数显著低于所有其他组;30 mg/mL ME1100组上皮衬液和血浆Cmax分别为31.1和1.2 mg/L,且生存率显著优于30 mg/mL阿米卡星。

要点

  • ME1100 10和30 mg/mL吸入可显著提高铜绿假单胞菌VAP小鼠生存率。
  • 30 mg/mL ME1100组初始治疗后6小时肺内细菌数显著低于所有其他组。
  • 30 mg/mL ME1100生存率显著优于同浓度阿米卡星,尽管ELF和血浆浓度无显著差异。

核心结论

  • ME1100在铜绿假单胞菌VAP小鼠模型中显示体内有效性,且优于阿米卡星。

研究设计与样本

  • 采用铜绿假单胞菌所致呼吸机相关肺炎小鼠模型,使用定制研究用雾化系统。
  • 小鼠每日一次治疗5分钟,分组为安慰剂、3、10或30 mg/mL ME1100或30 mg/mL阿米卡星。

主要发现

  • 生存研究中,10和30 mg/mL ME1100组生存率较安慰剂组显著提高。
  • 30 mg/mL ME1100组初始治疗后6小时肺内细菌数显著低于所有其他组。
  • 30 mg/mL ME1100组上皮衬液和血浆Cmax分别为31.1和1.2 mg/L。
  • 30 mg/mL ME1100与30 mg/mL阿米卡星的ELF和血浆浓度无显著差异,但ME1100生存率显著优于阿米卡星。

临床怎么用

  • 提示吸入ME1100可能作为铜绿假单胞菌VAP的潜在治疗选择,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Arbekacin is an aminoglycoside that shows strong antimicrobial activity against Gram-positive bacteria, including MRSA, as well as Pseudomonas aeruginosa . The therapeutic effectiveness of arbekacin is directly related to C max at the infection site. To maximize drug delivery to the respiratory tract and minimize the systemic toxicity, arbekacin optimized for inhalation, ME1100, is under development. In this study, we investigated the efficacy and pharmacokinetics of ME1100 in a murine model of ventilator-associated pneumonia caused by P. aeruginosa by using a customized investigational nebulizer system. METHODS: The mice were treated for 5 min, once daily, with placebo, 3, 10 or 30 mg/mL ME1100 or 30 mg/mL amikacin. RESULTS: In the survival study, the survival rate was significantly improved in the 10 and 30 mg/mL ME1100 treatment groups compared with that in the placebo group. The number of bacteria in the lungs was significantly lower in the 30 mg/mL ME1100 treatment group at 6 h after the initial treatment, compared with all other groups. In the pharmacokinetic study, the C max in the 30 mg/mL ME1100 treatment group in the epithelial lining fluid (ELF) and plasma was 31.1 and 1.2 mg/L, respectively. Furthermore, we compared the efficacy of ME1100 with that of amikacin. Although there were no significant differences in ELF and plasma concentrations between 30 mg/mL of ME1100 and 30 mg/mL of amikacin, ME1100 significantly improved the survival rate compared with amikacin. CONCLUSIONS: The results of our study demonstrated the in vivo effectiveness of ME1100 and its superiority to amikacin.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Kaku N, Morinaga Y, Takeda K, et al. Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa. J Antimicrob Chemother. 2017. PMID: 27999047. doi:10.1093/jac/dkw517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。